207 related articles for article (PubMed ID: 20558290)
1. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Markaverich BM; Vijjeswarapu M; Shoulars K; Rodriguez M
J Steroid Biochem Mol Biol; 2010 Oct; 122(4):219-31. PubMed ID: 20558290
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
Sakurai MA; Ozaki Y; Okuzaki D; Naito Y; Sasakura T; Okamoto A; Tabara H; Inoue T; Hagiyama M; Ito A; Yabuta N; Nojima H
PLoS One; 2014; 9(6):e100124. PubMed ID: 24971999
[TBL] [Abstract][Full Text] [Related]
3. Multiple Sites of Type II Site Ligand (Luteolin and BMHPC) Regulation of Gene Expression in PC-3 Cells.
Markaverich BM; Vijjeswarapu M
Int J Biomed Sci; 2012 Dec; 8(4):219-32. PubMed ID: 23675277
[TBL] [Abstract][Full Text] [Related]
4. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
[TBL] [Abstract][Full Text] [Related]
5. Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.
Shoulars K; Rodriguez MA; Thompson T; Markaverich BM
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):41-50. PubMed ID: 19837161
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
Bonaccorsi L; Marchiani S; Muratori M; Forti G; Baldi E
J Cancer Res Clin Oncol; 2004 Oct; 130(10):604-14. PubMed ID: 15258753
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
8. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
Mimeault M; Moore E; Moniaux N; Hénichart JP; Depreux P; Lin MF; Batra SK
Int J Cancer; 2006 Feb; 118(4):1022-31. PubMed ID: 16108016
[TBL] [Abstract][Full Text] [Related]
10. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839).
Höpfner M; Sutter AP; Gerst B; Zeitz M; Scherübl H
Br J Cancer; 2003 Nov; 89(9):1766-75. PubMed ID: 14583782
[TBL] [Abstract][Full Text] [Related]
11. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.
Meco D; Servidei T; Riccardi A; Ferlini C; Cusano G; Zannoni GF; Giangaspero F; Riccardi R
Neuro Oncol; 2009 Jun; 11(3):250-9. PubMed ID: 19033425
[TBL] [Abstract][Full Text] [Related]
13. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
14. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.
Koizumi F; Shimoyama T; Taguchi F; Saijo N; Nishio K
Int J Cancer; 2005 Aug; 116(1):36-44. PubMed ID: 15761868
[TBL] [Abstract][Full Text] [Related]
16. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
Wang H; Fei Z; Jiang H
J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
[TBL] [Abstract][Full Text] [Related]
17. Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
Jameson MJ; Taniguchi LE; VanKoevering KK; Stuart MM; Francom CR; Mendez RE; Beckler AD; Carlson HT; Thomas CY; Khalil AA
J Oral Pathol Med; 2013 Apr; 42(4):332-8. PubMed ID: 23106397
[TBL] [Abstract][Full Text] [Related]
18. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest.
Chan QK; Lam HM; Ng CF; Lee AY; Chan ES; Ng HK; Ho SM; Lau KM
Cell Death Differ; 2010 Sep; 17(9):1511-23. PubMed ID: 20203690
[TBL] [Abstract][Full Text] [Related]
19. Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
Watt HL; Rachid Z; Jean-Claude BJ
J Neurooncol; 2010 Dec; 100(3):345-61. PubMed ID: 20467786
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]